About Us

At Adiso, we create medicines to treat inflammatory diseases, improving the lives of patients and their families. Current treatment paradigms are far too often either inadequate to halt disease progression or burden the patient with significant safety concerns.

To tackle these challenges, we are advancing an innovative pipeline of small molecules and single strain live biotherapeutic products (SS-LBP) both with novel mechanisms of action.

ADS024 (SS-LBP) is currently being evaluated in a Phase 1b study for the prevention of recurrent CDI and a Phase 2 study in mild-to-moderate ulcerative colitis (UC). ADS051 is currently enrolling a Ph1b study in moderate-to-severe ulcerative colitis (UC). Adiso is also developing a novel dual inflammasome inhibitor in discovery phase which is being initially explored in respiratory inflammation, with multiple future therapeutic areas to pursue.

Team & Founders

Leadership Team

Scott Megaffin
Chief Executive Officer

Jennifer Locke
Chief Operating & Business Officer

Bharat Dixit, PhD
Chief Technology Officer

Shannon Foley
Head of Finance

Ashley Mansell, PhD
Head of Translational Science

Laurent Chesnel, PhD

Laurent Chesnel, PhD
Head of Research & Development

Chris Murphy, PhD
Head of Research & Development

Discovery Team

Single Strain Live Biotherapeutic Product (SS-LBP) Platform

Discovery

IND Enabling

Phase 1

Phase 2

Phase 3

ADS024

Prevention of CDI Recurrence

ADS024 is an oral single strain live biotherapeutic product (SS-LBP). A naturally occurring live biotherapeutic product, ADS024 possesses a dual mechanism of action. It is bactericidal toward Clostridioides difficile and degrades Toxins A and B produced by C. difficile while maintaining other components of the microbiome. ADS024 is a single strain multimodal LBP and is manufactured from a pure, clonal bacterial cell bank, yielding a standardized lyophilized drug product eliminating the need to directly source from donor fecal material.

ADS024

Ulcerative Colitis

ADS024 is an oral single strain live biotherapeutic product (SS-LBP). A naturally occurring live biotherapeutic product, ADS024 modulates inflammation as a single strain multimodal LBP and has been shown to reduce neutrophil trafficking through the colonic epithelium. ADS024 is manufactured from a pure, clonal bacterial cell bank, yielding a standardized lyophilized drug product eliminating the need to directly source from donor fecal material.

ADS00X

Neuroinflammation

ADS00X has demonstrated pre-clinical efficacy in 3 models of neuroinflammatory disease. Adiso is pursuing confirmatory evidence which supports the impact of our SS-LBP products on the Gut-Brain Axis.

Small Molecule Platform

Discovery

IND Enabling

Phase 1

Phase 2

Phase 3

ADS051

Ulcerative Colitis

ADS051 is an oral, gut-restricted, small molecule modulator of neutrophil trafficking and activation for the treatment of ulcerative colitis. ADS051 blocks MRP2 release of HXA3 gradient, while also blocking FPR1 activation of neutrophils within the colonic epithelium.  Unlike currently available therapies, this addresses neutrophil-mediated tissue damage, a hallmark of UC pathology. In a healthy volunteer study, ADS051 was safe and well-tolerated and restricted to the gut with limited systemic exposure.

ADS032

Respiratory Inflammation

ADS032 is a novel small molecule inhibitor that locally blocks two types of inflammasomes simultaneously, NLRP1 and NLRP3 – the innate immune system’s receptors and first line sensors of pathogens and other danger signals. Chronic activation of NLRP1 and NLPR3 is directly implicated in a wide range of inflammation-triggered conditions across multiple organ systems. By targeting both NLRP3 and NLRP1, ADS032 may provide a comprehensive anti-inflammatory approach across a range of diseases.

Contact Us